Psoriatic Arthritis Journal Scan: May 2019

The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies.

Kavanaugh A, Gottlieb A, Morita A, et al. Ann Rheum Dis. 2019 May 21. 

An integrated analysis to determine the contribution of joint and skin improvements to health-related quality of life (HRQoL) in patients with psoriatic arthritis (PsA). Optimal improvements in patients' HRQoL were dependent on successful treatment of both joint and skin symptoms.

Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis.

Cella D, Wilson H, Shalhoub H, et al. J Patient Rep Outcomes. 2019 May 20;3(1):30.

One-on-one semi-structured qualitative interviews with adult patients evaluated the measurement properties (e.g., content validity, reliability, and ability to detect change) of the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale in patients with active psoriatic arthritis (PsA). Fatigue was confirmed to be an important symptom to patients with PsA, and FACIT-Fatigue was found to be a reliable and valid measure in this population.

Birth Outcomes and Disease Activity during Pregnancy in a Prospective Cohort of Women with Psoriatic Arthritis and Ankylosing Spondylitis.

Smith CJF, Bandoli G, Kavanaugh A, Chambers CD. Arthritis Care Res (Hoboken). 2019 May 10.

Women with PsA and AS have increased risk for selected adverse pregnancy outcomes. Compared to healthy controls (n=717), PsA (n = 117) was associated with increased risk for moderate preterm delivery (32-36 weeks' gestation), oligohydramnios, and Caesarean delivery. Active disease and corticosteroid use may increase the risk for some adverse pregnancy outcomes in women with these conditions.

Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis.

Alivernini S, Bruno D, Tolusso B, et al. Arthritis Res Ther. 2019 May 9;21(1):116.

The aim of the study was to identify synovial tissue (ST) biomarkers differentially expressed in PsA and seronegative rheumatoid arthritis and test their predictive value of therapeutic response. Histological analysis of ST may help to solve the clinical overlap between the two diseases and provides prognostic data about the therapy success.

Psoriatic arthritis - new perspectives.

Krakowski P, Gerkowicz A, Piertrzak A, et al. Arch Med Sci. 2019 May;15(3):580-589.

The management of PsA requires the care of a multidisciplinary team, which should include dermatologists, rheumatologists, physiotherapists, and orthopedic surgeons. PsA should be diagnosed as early as possible to slow down joint damage and progression of disability.

The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies.

Kavanaugh A, Gottlieb A, Morita A, et al. Ann Rheum Dis. 2019 May 21. 

An integrated analysis to determine the contribution of joint and skin improvements to health-related quality of life (HRQoL) in patients with psoriatic arthritis (PsA). Optimal improvements in patients' HRQoL were dependent on successful treatment of both joint and skin symptoms.

Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis.

Cella D, Wilson H, Shalhoub H, et al. J Patient Rep Outcomes. 2019 May 20;3(1):30.

One-on-one semi-structured qualitative interviews with adult patients evaluated the measurement properties (e.g., content validity, reliability, and ability to detect change) of the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale in patients with active psoriatic arthritis (PsA). Fatigue was confirmed to be an important symptom to patients with PsA, and FACIT-Fatigue was found to be a reliable and valid measure in this population.

Birth Outcomes and Disease Activity during Pregnancy in a Prospective Cohort of Women with Psoriatic Arthritis and Ankylosing Spondylitis.

Smith CJF, Bandoli G, Kavanaugh A, Chambers CD. Arthritis Care Res (Hoboken). 2019 May 10.

Women with PsA and AS have increased risk for selected adverse pregnancy outcomes. Compared to healthy controls (n=717), PsA (n = 117) was associated with increased risk for moderate preterm delivery (32-36 weeks' gestation), oligohydramnios, and Caesarean delivery. Active disease and corticosteroid use may increase the risk for some adverse pregnancy outcomes in women with these conditions.

Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis.

Alivernini S, Bruno D, Tolusso B, et al. Arthritis Res Ther. 2019 May 9;21(1):116.

The aim of the study was to identify synovial tissue (ST) biomarkers differentially expressed in PsA and seronegative rheumatoid arthritis and test their predictive value of therapeutic response. Histological analysis of ST may help to solve the clinical overlap between the two diseases and provides prognostic data about the therapy success.

Psoriatic arthritis - new perspectives.

Krakowski P, Gerkowicz A, Piertrzak A, et al. Arch Med Sci. 2019 May;15(3):580-589.

The management of PsA requires the care of a multidisciplinary team, which should include dermatologists, rheumatologists, physiotherapists, and orthopedic surgeons. PsA should be diagnosed as early as possible to slow down joint damage and progression of disability.

The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies.

Kavanaugh A, Gottlieb A, Morita A, et al. Ann Rheum Dis. 2019 May 21. 

An integrated analysis to determine the contribution of joint and skin improvements to health-related quality of life (HRQoL) in patients with psoriatic arthritis (PsA). Optimal improvements in patients' HRQoL were dependent on successful treatment of both joint and skin symptoms.

Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis.

Cella D, Wilson H, Shalhoub H, et al. J Patient Rep Outcomes. 2019 May 20;3(1):30.

One-on-one semi-structured qualitative interviews with adult patients evaluated the measurement properties (e.g., content validity, reliability, and ability to detect change) of the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale in patients with active psoriatic arthritis (PsA). Fatigue was confirmed to be an important symptom to patients with PsA, and FACIT-Fatigue was found to be a reliable and valid measure in this population.

Birth Outcomes and Disease Activity during Pregnancy in a Prospective Cohort of Women with Psoriatic Arthritis and Ankylosing Spondylitis.

Smith CJF, Bandoli G, Kavanaugh A, Chambers CD. Arthritis Care Res (Hoboken). 2019 May 10.

Women with PsA and AS have increased risk for selected adverse pregnancy outcomes. Compared to healthy controls (n=717), PsA (n = 117) was associated with increased risk for moderate preterm delivery (32-36 weeks' gestation), oligohydramnios, and Caesarean delivery. Active disease and corticosteroid use may increase the risk for some adverse pregnancy outcomes in women with these conditions.

Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis.

Alivernini S, Bruno D, Tolusso B, et al. Arthritis Res Ther. 2019 May 9;21(1):116.

The aim of the study was to identify synovial tissue (ST) biomarkers differentially expressed in PsA and seronegative rheumatoid arthritis and test their predictive value of therapeutic response. Histological analysis of ST may help to solve the clinical overlap between the two diseases and provides prognostic data about the therapy success.

Psoriatic arthritis - new perspectives.

Krakowski P, Gerkowicz A, Piertrzak A, et al. Arch Med Sci. 2019 May;15(3):580-589.

The management of PsA requires the care of a multidisciplinary team, which should include dermatologists, rheumatologists, physiotherapists, and orthopedic surgeons. PsA should be diagnosed as early as possible to slow down joint damage and progression of disability.